Fig 1.
Simplified decision tree model for the analyses of the cost-effectiveness of intralesional infiltration, in comparison with parenteral use of meglumine antimoniate, in the treatment of cutaneous leishmaniasis.
IL-MA: meglumine antimoniate intralesional infiltration; EV-MA: endovenous meglumine antimoniate therapy; p_adverse eventes_IL: probability of adverse events during IL-MA; p_adverse eventes_EV: probability of adverse events during during EV-MA; cure_SIST: cure rate for endovenous meglumine antimoniate therapy; cure_IL: cure rate for meglumine antimoniate intralesional infiltration; c_IL_AM: total cost for meglumine antimoniate intralesional infiltration; c_SIST_AM: total cost for endovenous meglumine antimoniate therapy; c_AE_IL_AM: total cost related to adverse events during IL-MA; c_AE_SIST: total cost related to adverse events during EV-MA.
Table 1.
The costs related to meglumine antimoniate intralesional infiltration and to endovenous meglumine antimoniate treatment.
Table 2.
The costs related to adverse events to meglumine antimoniate intralesional infiltration and to endovenous meglumine antimoniate treatment.
Table 3.
Cost-effectiveness analysis of meglumine antimoniate intralesional infiltration compared to endovenous meglumine antimoniate for cutaneous leishmaniasis treatment in Brazil.
Fig 2.
Tornado diagram of deterministic sensitivity analysis.
Notes: Vertical line represents final ICER. Critical variables are represented as horizontal bars. All variables crossed final ICER, which means that none of them was able to affect the result. cure_SIST: cure rate for endovenous meglumine antimoniate therapy; cure_IL: cure rate for meglumine antimoniate intralesional infiltration; c_IL_AM: total cost for meglumine antimoniate intralesional infiltration; c_SIST_AM: total cost for endovenous meglumine antimoniate therapy; c_AE_IL_AM: total cost related to adverse events during IL-MA; c_AE_SIST: total cost related to adverse events during EV-MA.
Fig 3.
Cost-effectiveness acceptability curve.
MA: meglumine antimoniate; IL-MA: meglumine antimoniate intralesional infiltration.